Clearpol's Opinion of this Guidance as of 09/26/2023
Guidance recommending that all SNF residents with symptomatic COVID-19 be evaluated by a prescribing clinician to be considered for oral COVID-19 therapeutics. SNFs should evaluate all residents for any drug-drug interaction risk, and/or renal and hepatic impairment in advance of a COVID-19 diagnosis and indicate such information in charts to facilitate access to appropriate therapeutics when a COVID-19 diagnosis is made.
Also provides information regarding available guidance and resources for evaluating, prescribing, and obtaining COVID-19 therapeutics for SNF residents and recommends SNFs provide information on appropriate therapeutics to their HCP who have symptomatic COVID-19. Includes the latest authorized COVID-19 treatments, with the recommended timing for effectiveness.
SNF residents continue to be at high risk for severe illness, hospitalization and death from COVID-19. COVID-19 therapeutics can substantially reduce these risks. All SNF residents should be considered eligible to receive treatment for mild-to-moderate COVID-19 and should be evaluated by a prescribing healthcare provider for consideration of COVID-19 therapeutics. For treatment to be effective, it must be started within the timeframes in the table below. The products currently approved or authorized for treating mild-to-moderately ill COVID-19 patients include the following:
The decision to not prescribe COVID-19 treatment should be reserved for situations in which the risk of prescribing clearly outweighs the benefits of treatment in preventing hospitalization, death, and the potential for reduced risk of long COVID.
Additional information and resources for healthcare providers and SNFs can be found in CDPH COVID-19 Treatments Resources for Providers webpage and the SNF Surge Readiness Fact Sheet.
SNFs should provide information for their HCP who test positive for COVID-19 to obtain treatment with appropriate therapeutics. SNF HCP may seek care from their regular healthcare provider or visit the California for All COVID-19 Treatment webpage if they have trouble connecting with their healthcare provider for COVID-19 treatment evaluation.
Clearpol Inc. does not make any guarantees regarding the accuracy of the opinions provided on our platform. Please use your own judgement.
Clearpol's Summary of this Guidance
The California Department of Public Health issued a letter recommending that all Skilled Nursing Facility (SNF) residents with symptomatic COVID-19 be evaluated for potential treatment with COVID-19 therapeutics. The letter also advises SNFs to assess all residents for potential drug interactions and kidney or liver impairments before a COVID-19 diagnosis. The letter includes information about available treatments and their effectiveness. It also notes that as of May 2023, only 40% of weekly COVID-19 cases in SNFs were treated with therapeutics. The letter urges SNFs to ensure their pharmacy has sufficient supplies of oral antiviral therapeutics and to provide information to their healthcare personnel about obtaining treatment if they test positive for COVID-19.
Clearpol Inc. does not make any guarantees regarding the accuracy of the opinions or summaries provided on our platform. Please use your own judgement.
You have 0 new tasks available
Below are AI generated tasks related to this document. Accept or deny a task.
No suggested tasks available at the moment!
AI generated tasks related to this document are shown here. Tasks may be coming soon or you may have accepted/denied all the available tasks for this document.
The document is ready to print
Click below to print the document in a new window. When finished, you can return to this tab to continue.
Copy Document Link
Please enter a Name.
Please enter a valid email address.
Please enter a first name.
Please enter a last name.
Please enter a valid email address.